Litcius/Paper detail

Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer

Yoshihisa Tokumaru, Masanori Oshi, Michelle R. Huyser, Li Yan, Masahiro Fukada, Nobuhisa Matsuhashi, Manabu Futamura, Yukihiro Akao, Kazuhiro Yoshida, Kazuaki Takabe

2021Scientific Reports22 citationsDOIOpen Access PDF

Abstract

Advanced gastric cancer (GC) is one of the most lethal cancer types, thus a better understanding of its biology in patients is urgently needed. MicroRNA (miR)-29a is a known tumor suppressive miR that is related to metastasis, but its clinical relevance in GC remains ambiguous. Here, using a large GC patient cohort we hypothesized that low expression of miR-29a in GC is associated with aggressive cancer biology and worse survival. We demonstrated that low miR-29a GC enriched cell proliferation, apoptosis, metastasis, and angiogenesis related gene sets, as well as the higher expression of related genes. Low miR-29a GC was associated with less anti-cancer immune cell infiltration as well as immune related scoring. Low miR-29a GC demonstrated a worse overall survival (OS) as well as disease specific survival (DSS) compared with high expressing miR-29a GC. Notably, low miR-29a expression was the only factor, other than residual tumor status, to be an independent prognostic biomarker of worse OS and DSS. In conclusion, low miR-29a GC was associated with aggressive cancer biology and worse OS as well as DSS. Additionally, low expression of miR-29a was an independent prognostic biomarker of OS and DSS in gastric cancer patients.

Topics & Concepts

BiomarkerCancerMetastasismicroRNAOncologyAngiogenesisImmune systemMedicineBiologyCancer researchImmunologyInternal medicineGeneBiochemistryMicroRNA in disease regulationCancer-related molecular mechanisms researchCircular RNAs in diseases
Low expression of miR-29a is associated with aggressive biology and worse survival in gastric cancer | Litcius